poisar

Stocks · News reference

Edesa Biotech Enters Exclusive Licensing Agreement with KYORIN Pharmaceutical for Paridiprubart in Japan

Fiscal.ai

Edesa Biotech has signed an exclusive collaboration and license agreement with KYORIN Pharmaceutical to develop and commercialize its drug candidate, paridiprubart, for Acute Respiratory Distress Syndrome (ARDS) in Japan.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading